gvtcx

supplier

Celix Pharma Ltd.

HA63SE combined from 3 published records

as a supplier

20 recorded awards from 4 buyers , between 24 Mar 2025 and 3 Jun 2026.

awards won
20
exclusive
0%
0 sole-winner awards
median award
£16.8m
largest
£16.8m

“Exclusive” means this organisation was the only one awarded under that procurement; the rest were shared with other suppliers, typically on a framework.

sells to

contracts won

contractbuyervalueawarded
Transitional Drugs 7 shared NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) £16,804,001 3 Jun 2026
NHS National Framework for Transition Products (Nintedanib and Dalbavancin) shared NHS England £14,758,000 25 Feb 2026
NHS National Generic Pharmaceuticals - Wave 15c shared NHS England £17,727,000 13 Jan 2026
NHS National Generic Pharmaceuticals - Wave 15c shared NHS England £403,702,000 13 Jan 2026
NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin shared NHS England £25,881,000 25 Nov 2025
NHS Framework Agreement for Branded Medicines - Proprietary Category Tender shared NHS England £1,241,520,444 24 Mar 2025
NHS National Framework for Transition Products (Nintedanib and Dalbavancin) shared NHS England · 24 Apr 2026
NP49425 Generic and Biosimilar Transition Medicines shared The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) · 30 Mar 2026
NP49425 Generic and Biosimilar Transition Medicines shared The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) · 30 Mar 2026
NP49425 Generic and Biosimilar Transition Medicines shared The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) · 30 Mar 2026
NP49425 Generic and Biosimilar Transition Medicines shared The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) · 30 Mar 2026
NP49425 Generic and Biosimilar Transition Medicines shared The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) · 30 Mar 2026
NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin shared NHS England · 30 Jan 2026
NHS National Generic Pharmaceuticals Wave 15b shared NHS England · 4 Aug 2025
NHS National Generic Pharmaceuticals Wave 15b shared NHS England · 4 Aug 2025
NP35925 Cardiovascular & Respiratory Medicines shared The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) · 6 May 2025
NP35925 Cardiovascular & Respiratory Medicines shared The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) · 6 May 2025
NHS Framework Agreement for Branded Medicines - Proprietary Category Tender - 1 May 2025 shared NHS England · 22 Apr 2025
NP39724 Generic and Biosimilar Cancer Medicines shared The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) · 27 Feb 2025
NP Generic Medicines Transition Tender (October 2023) shared The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") · 26 Sept 2023

every contract won by Celix Pharma Ltd. →

as published

This page combines 3 separate records from the source data. Every one is listed below exactly as the publisher filed it, so you can check the grouping yourself.

name as publishedidentifierpostcoderecords
Celix Pharma Ltd. · HA6 3SE 13
CELIX PHARMA LTD GB-COH 12474195 E16 2DQ 4
Celix Pharma Ltd GB-PPON PDZD-6425-PVYX E16 2DQ 3

why these were combined

Matching uses organisation identifiers where publishers provide them, falling back to name and address. Records are never combined on address alone, because one shared-service postcode carries 244 different organisations. how this works